| |
|
|
Boryung Pharmaceutical (003850) |
|
|
STOCK |
|
|
| Address |
BORYUNG BLDG., 66-21, WONNAM-DONG, JONGNO-GU, SEOUL |
| Home Page |
www.boryung.co.kr
|
| Established |
1963.11.11 |
Tel |
02-708-8000 |
| Listed |
1988.10.24 |
IR |
02-708-8086 |
| Common shares O/S |
3,020,000 |
President |
Kim,Eun Seon/Kim,Gwang Ho |
| Preferred shares O/S |
|
No.of Employees |
861(2009. 9) |
| Sales increased on rising demand for its key products such as Gelfos and increased drug prices. Its operating income ratio rose on declined fixed costs, although its R&D spending increased. Its R&D spending against total sales increased as it sought to develop new drugs and cancer drugs. |
| Sales are expected to increase on rising demand for new products such Perisys, and imminent release of a new drug called ARB. Profitability is expected to improve on increasing sales and improving non-operating income. The company secured diversified revenue sources by developing new drugs. |
|
  |
(date: 2009.06, unit : %) |
| Name |
Boryung |
Kim Eun-seon |
BBH-GMOEMGMKTFD |
| Portion |
29.2 |
12.1 |
6.6 |
|
 |
(unit : %) |
| Sales |
Gelpos M |
7.2 |
Cost |
Raw Materials |
|
| Cinalong |
6.4 |
Labors |
|
| Others |
74.0 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
04. 4 |
06. 4 |
07. 4 |
08. 4 |
09. 4 |
| Type |
SD |
SD |
SD |
SD |
SD |
| Amount |
3.00 |
3.00 |
3.00 |
3.00 |
3.00 |
|
|
|
|
